 | |
| Headquarters | Lugano, Switzerland |
|---|---|
Membership | 40,000 |
Official language | English |
Staff | 125 |
| Website | esmo.org |
The European Society for Medical Oncology (ESMO) is a professional organisation for medical oncology. With more than 40,000 members representing oncology professionals from over 177 countries worldwide, ESMO was founded in 1975. [1]
Founded in 1990, ESMO’s flagship scientific journal, Annals of Oncology , publishes articles addressing medical oncology, surgery, radiotherapy, pediatric oncology, basic research and the comprehensive management of patients with malignant diseases. Annals of Oncology is the official journal of ESMO and from 2008 of the Japanese Society for Medical Oncology (JSMO)[ citation needed ]
The ESMO Clinical Practice Guidelines (CPG) are intended to provide oncology professionals with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. Each Clinical Practice Guideline includes information on the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up designed to help oncologists deliver an appropriate quality of care to their patients.[ citation needed ]
The annual ESMO Congress is attended by 30,000 participants. The congress presents the latest scientific developments in basic, translational and clinical cancer research and contextualises new findings for practical implementation in every day patient care.
ESMO publishes handbooks, scientific meeting reports, and medical oncology training guidelines. The Society provides fellowships for research training for young oncologists, an Exam in Medical Oncology and an accreditation program for institutes providing patients with integrated supportive and palliative care. Through an online professional networking platform ESMO members collaborate, interact and share knowledge on topics of research and clinical practice.[ citation needed ]
In 2015, ESMO published the first version of its Magnitude of Clinical Benefit Scale to grade the magnitude of clinical benefit of cancer therapies incorporating efficacy, long-term survival and side-effects of any anticancer agent into a single score. [2] ESMO-MCBS was updated with the publication of the version 1.1 in 2017. [3] Forms are available from the official website of ESMO.
M. Krishnan Nair was an Indian oncologist. He was the founding director of the Regional Cancer Centre, Thiruvananthapuram, a director of the S.U.T. Institute of Oncology, and Trivandrum Cancer Center(TCC), part of SUT Royal Hospital in Thiruvananthapuram (Trivandrum) and a professor at the Amrita Institute of Medical Sciences & Research in Kochi. The Government of India awarded him the fourth highest civilian award of the Padma Shri in 2001 for his contributions in the cancer care field.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less time between treatments than in a standard chemotherapy treatment plan.
Martine J. Piccart-Gebhart is a Belgian medical oncologist. She is a professor of oncology at the Université Libre de Bruxelles and scientific director at the Jules Bordet Institute in Brussels, Belgium. She is also a member of the Belgian Royal Academy of Medicine.
Geriatric oncology is a branch of medicine that is concerned with the diagnosis and treatment of cancer in the elderly, usually defined as aged 65 and older. This fairly young but increasingly important subspecialty incorporates the special needs of the elderly into the treatment of cancer.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
Professor David James Kerr CBE is a British Cancer Researcher. His primary area of research is treatment and management of colorectal cancer.
Peter Boyle, FRSE FFPH FRCPS(Glas) FRCP(Edin) FMedSci, was a British epidemiologist. He conducted research on globalisation of cancer, where he showed the dramatic increase of cancer in low- and medium income countries.
ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein, most frequently, the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. Less frequently, there will be novel translocation partners for the ALK gene, in place of EML4. This abnormal gene fusion leads to the production of a protein that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells.
Cora Sternberg is an American medical oncologist.
Cancer and nausea are associated in about fifty percent of people affected by cancer. This may be as a result of the cancer itself, or as an effect of the treatment such as chemotherapy, radiation therapy, or other medication such as opiates used for pain relief. About 70–80% of people undergoing chemotherapy experience nausea or vomiting. Nausea and vomiting may also occur in people not receiving treatment, often as a result of the disease involving the gastrointestinal tract, electrolyte imbalance, or as a result of anxiety. Nausea and vomiting may be experienced as the most unpleasant side effects of cytotoxic drugs and may result in patients delaying or refusing further radiotherapy or chemotherapy.
Matthias Preusser is an Austrian oncologist and Professor of Medical Oncology as well as Head of the Clinical Division of Oncology at the Medical University of Vienna. He is known for his work on neurooncology, Molecular Therapy targets and biomarkers and immunotherapy of cancer.
Kathleen I. Pritchard, is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada, specializing in breast cancer therapies, and leading the clinical trials division of the centre. She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research methodology. According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014 and 2015.
Christoph Zielinski is an Austrian physician and cancer researcher. A medical oncologist, Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University of Vienna.
Functional Assessment of Cancer Therapy - General (FACT-G) is a patient-reported outcome measure used to assess health-related quality of life in patients undergoing cancer therapy. The FACT-G is the original questionnaire that led to the development of the larger Functional Assessment of Chronic Illness Therapy (FACIT) collection of quality of life instruments. The survey assesses the impacts of cancer therapy in four domains: physical, social/family, emotional, and functional. The FACT-G is also offered with additional questions measuring cancer-specific factors that may affect quality of life, leading to the creation of the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N), the Functional Assessment of Cancer Therapy - Lung (FACT-L), and 18 others.
Ashok K. Vaid is an Indian medical oncologist, known for his pioneering efforts in bone marrow transplantation in India. He is credited with the performance of the first 25 bone marrow transplantations in the private sector in North India. He heads the Cancer Institute- Division of Medical Oncology and Haemotology at Medanta The Medicity.
Cancer is one of the underlying diseases that increases the risk of COVID-19 developing to a serious illness.
G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.
Sherene Loi is an Australian oncologist. She is the 2021 winner of the Australian Prime Ministers Prize for Science, in the category of Frank Fenner Prize for Life Scientist of the Year. Loi is Head of Translational Breast Cancer Research, within the Peter Macallum Cancer Centre. Loi's research has advanced understanding into breast cancer, developing and implementing an immune system biomarker. This biomarker will enable improved management for people with advanced cancer. This biomarker is now part of routine pathology reporting across many countries and also is included in the World Health Organization Classification of Tumours.
Zanzalintinib is an oral drug that is undergoing clinical studies. It could potentially be used to treat renal cell carcinoma (RCC). It is being developed by Exelixis.
| International | |
|---|---|
| National | |
| Other | |
